ProQR (NASDAQ: PRQR) director details substantial share and long-dated option holdings

Rhea-AI Filing Summary

ProQR Therapeutics N.V. director Valerio Domenico filed an initial ownership report showing his equity position in the company. He directly holds 420,729 Ordinary Shares and has additional indirect exposure through a Valerio family foundation, for which he disclaims beneficial ownership except for any pecuniary interest.

He also holds multiple employee share options over Ordinary Shares with exercise prices ranging from $1.98 to $15.78 per share and expiration dates between 2026 and 2035. These options give him rights to buy additional shares over time as they vest, aligning part of his compensation with ProQR’s long-term share performance.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Valerio Domenico

(Last) (First) (Middle)

PROQR THERAPEUTICS N.V.

ZERNIKEDREEF 9

(Street)

LEIDEN 2333 CK

(City) (State) (Zip)

NETHERLANDS

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ProQR Therapeutics N.V. [ PRQR ]

3a. Foreign Trading Symbol
[N/A]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	420,729	D
Ordinary Shares	304,963	I	See footnote(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(2)	06/20/2026	Ordinary Shares	5,815	$4.89	D
Share Option (Right to Buy)	(2)	12/31/2026	Ordinary Shares	32,164	$4.9	D
Share Option (Right to Buy)	(2)	12/31/2027	Ordinary Shares	27,500	$3.3	D
Share Option (Right to Buy)	(2)	12/31/2028	Ordinary Shares	14,918	$15.78	D
Share Option (Right to Buy)	(2)	12/31/2029	Ordinary Shares	24,615	$9.91	D
Share Option (Right to Buy)	(2)	12/31/2030	Ordinary Shares	23,239	$4.2	D
Share Option (Right to Buy)	(2)	02/29/2032	Ordinary Shares	23,931	$8.01	D
Share Option (Right to Buy)	(3)	12/31/2032	Ordinary Shares	22,608	$3.41	D
Share Option (Right to Buy)	(4)	12/31/2033	Ordinary Shares	23,489	$1.98	D
Share Option (Right to Buy)	(5)	12/31/2034	Ordinary Shares	22,128	$2.65	D
Share Option (Right to Buy)	(6)	12/31/2035	Ordinary Shares	25,192	$2.02	D

Explanation of Responses:

1. Shares held by Valerio family foundation, Stichting Administratiekantoor Endavit, for which the Reporting Person is the managing director. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such shares for purposes of Section 16 of the Exchange Act, or for any other purpose.

2. Fully vested.

3. 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

4. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

5. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

6. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Pieter Erik de Ridders, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Form 3 filing by Valerio Domenico at PRQR show?

The Form 3 shows director Valerio Domenico’s existing ownership in ProQR Therapeutics N.V., including direct Ordinary Shares and multiple share options. It provides a baseline of his equity position as he becomes subject to insider reporting rules.

How many ProQR (PRQR) shares does Valerio Domenico hold directly and indirectly?

Valerio Domenico directly holds 420,729 Ordinary Shares of ProQR. An additional 304,963 Ordinary Shares are held indirectly through a Valerio family foundation, where he is managing director and disclaims beneficial ownership except for any pecuniary interest.

What share options does Valerio Domenico report in his PRQR Form 3?

He reports several Share Options (Rights to Buy) ProQR Ordinary Shares, with exercise prices between $1.98 and $15.78 per share and expiration dates from 2026 through 2035, reflecting long-dated equity incentives tied to continued service and vesting.

How are Valerio Domenico’s indirect ProQR (PRQR) holdings structured?

Indirect holdings are held by the Valerio family foundation, Stichting Administratiekantoor Endavit, where he is managing director. He disclaims beneficial ownership of these shares for Section 16 purposes, except to the extent of any pecuniary interest he may have in them.

Do the options in Valerio Domenico’s PRQR Form 3 vest over time?

Yes. Footnotes describe options where 25% of shares vest on specific January 1 dates from 2024 through 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments, contingent on his continued service to ProQR on each vesting date.